Bio-Techne Corporation Bio-Techne Corporation

Bio-Techne Corporation

TECH

Rang in Aktien #1871
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Aktienkurs
$72.55
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$11.38B
Veränderung (1 Tag)
0.03%
Veränderung (1 Jahr)
17.27%
Land
US
Handel Bio-Techne Corporation (TECH)

Kategorie

Healthcare
P/S-Verhältnis für Bio-Techne Corporation (TECH)
P/S-Verhältnis zum October 2026 TTM: 9.36
Laut den neuesten Finanzberichten und dem Aktienkurs von Bio-Techne Corporation beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 9.36. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 9.74.
P/S-Verlauf für Bio-Techne Corporation von 2000 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 9.36 40.71%
2025 6.65 -31.80%
2024 9.74 -13.68%
2023 11.29 -8.20%
2022 12.30 -34.38%
2021 18.74 37.22%
2020 13.66 23.32%
2019 11.07 28.41%
2018 8.62 10.72%
2017 7.79 -7.33%
2016 8.40 4.04%
2015 8.08 -15.36%
2014 9.54 15.48%
2013 8.26 -5.15%
2012 8.71 -18.30%
2011 10.67 34.09%
2010 7.95 -12.95%
2009 9.14 -22.36%
2008 11.77 16.68%
2007 10.09 2.78%
2006 9.81 -5.40%
2005 10.37 -6.18%
2004 11.06 27.66%
2003 8.66 -1.89%
2002 8.83 -24.43%
2001 11.68 -54.06%
2000 25.43 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
10.02 7.11%
US
40.55 333.36%
US
3.96 -57.67%
AU
- -
CH
10.15 8.43%
NL